Written by
Share article:
In early June, Sectra announced the launch of its new diagnostic IT module for genomics within molecular pathology. The module, which will be integrated with Sectra’s other solutions for radiology and pathology as part of its enterprise imaging platform, was developed in collaboration with the University of Pennsylvania Health System in the US. The vendor highlights that the module will enable hospitals to predict how individual cancer patients may respond to different treatments based on genomic information.
This announcement represents the culmination of nearly two years’ work for Sectra, which originally announced its genomics business unit and collaboration with the University of Pennsylvania Health System in 2022. The vendor’s IT solution may finally be ready for commercialisation, but could it be too soon for the market?
